RxSight, Inc. is classed by the SEC under Ophthalmic Goods (industry code 3851), based in Aliso Viejo, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $134 million and a loss of $39 million (its filed statements).
Product businessOphthalmic GoodsAliso Viejo, CAfilings since 20028 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3851, Ophthalmic Goods); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.0 out of ten, 8 of 9 metrics filed and 1 estimated: past 5.1 out of ten, present 4.6 out of ten, future 5.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 6.9 out of ten. No warning events in its filings since 2017. 69th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.9 out of ten. +55.7% a year over 6 filed years; profitable in 1 of 6. 59th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 0.6 out of ten. CrossAssetData estimate 0.6/10, confidence 35 of 100 (one part). 6th percentile among 8 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 4.7 out of ten. ROE -14%: lost 14¢ per shareholder dollar. Leverage 12%: owes 12¢ per asset dollar. 47th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.4 out of ten. bottom 44% of 8 in its family; net margin -29%. 44th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 4.4 out of ten. bottom 44% of 6 in its family for leadership; chief executive since 2026. 44th percentile among 6 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 6.8 out of ten. top 32% of 8 in its family for room to expand. 68th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 4.5 out of ten. bottom 45% of 8 in its family for growth drivers. 45th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 4.8 out of ten. bottom 48% of 8 in its family for expectations against reality. 48th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-25 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-09-16. Filings on record since 2002. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Rxlal 80%, LDD 15%, Service Warranty Service Contracts and Accessories 4%. As tagged in its annual report (Form 10-K, filed 2026-02-25).
Who runs it
Mottiwala, Aziz (President and CEO); Wilterding, Mark (Chief Financial Officer); Goldshleger, Ilya (Chief Operating Officer); Weinberg, Eric (Chief Business Development Officer); Kurtz, Ronald M Md (Chief Medical Officer); Gaines, Scott (Chief Customer Officer); Andrews, Julie (director); Cohen, Raymond W (director); Corley, Jesse Anderson (director); Fountain, Tamara (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.